Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy.

14%), the primary endpoint of OS did not reach statistical significance (median OS: 10.3 months vs. 9.0 months, HR = 0.86) [ 169 ].

also in 111,027 other papers

A series of subsequent key studies, such as the ALFA-0701 Phase III trial, demonstrated that fractionated lower doses (3 mg/m 2 on days 1, 4, and 7) of GO combined with chemotherapy significantly improved event-free survival, reducing the risk by 34%, and showed a trend towards OS benefit compared to chemotherapy alone in newly diagnosed CD33-positive AML patients [ 112 ].

also in 53,322 other papers